Reaching a New APEX; Betrixaban vs. Enoxaparin for Thromboprophylaxis

Achal Patel, Mercer University College of Pharmacy

Venous thromboembolism (VTE) is the third leading cause of vascular diagnosis following heart attack and stroke. [1] It is categorized into two types: deep vein thrombosis (DVT) and pulmonary embolism (PE). Venous thromboembolism affects men and women of all ages, and patients that are immobilized are at a higher risk. [1]

The Chest Guidelines recommend anticoagulants for up to two weeks after hospital discharge. [2] However, the risk of a VTE remains increased for at least a month. Therefore, Bevyxxa® (betrixaban), which is a direct and selective factor Xa inhibitor, was tested for extended-duration therapy for thromboprophylaxis in acutely ill medical patients. [3]

Continue reading


EINSTEIN’s CHOICE for Treatment of Venous Thromboembolism

Dakota T. Craft, Mercer University College of Pharmacy

Venous thromboembolism (VTE) is a blood clot that starts in a vein and includes deep vein thrombosis (DVT) and pulmonary embolism (PE).  The development of VTE may be provoked or idiopathic in origin.  This condition can occur at any age, but is most common in adults over 60. [1]  A history of VTE is the main risk factor for recurrent VTE, with a risk of recurrence as high as 53% in 10 years. [2]

Goals of therapy include decreasing mortality and preventing thrombus embolization and recurrence.  Per the American College of Chest Physicians 2016 guidelines for the treatment of VTE, first line treatment options for VTE include dabigatran, rivaroxaban, apixaban or edoxaban, while vitamin K antagonists are second line.  Duration of therapy often depends on the patient’s calculated risk of recurrence, with some indications for indefinite anticoagulation treatment. [3]  Physicians may choose to treat with aspirin rather than anticoagulants after 6- 12 months due to concerns of bleeding. [4]
Continue reading

Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy

Catherine Lister, Mercer University College of Pharmacy

The Center for Disease Control and Prevention (CDC) estimates that there are 900,000 people affected by venous thromboembolism (VTE) and pulmonary embolism (PE) every year in the United States. They approximate that 60,000 to 100,000 Americans die annually from these conditions. [1]

It is suggested that patients with active malignancy are at an increased risk of VTE and an increased risk of major bleeding when they have a VTE. [2] Continue reading

Innohep® (tinzaparin) vs Coumadin® (warfarin) for Treatment of Acute Venous Thromboembolism in Patients with Active Cancer

Julie Murphy, Mercer University College of Pharmacy

The American Journal of Preventive Medicine reports that while the actual number of venous thromboembolisms (VTE) is unknown, there are an estimated 300,000 to 600,000 cases in the United States annually. It is suggested that there is roughly one case per 100,000 young individuals and that risk increases to nearly one per 100 patients over the age of 80 years old. They define VTE as the inappropriate clotting of blood which can lead to a serious condition such as deep vein thrombosis (DVT) or pulmonary embolism (PE).1

Continue reading